Hisamitsu Pharmaceutical Co Inc
TSE:4530

Watchlist Manager
Hisamitsu Pharmaceutical Co Inc Logo
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Watchlist
Price: 4 137 JPY -0.27% Market Closed
Market Cap: 321.6B JPY

Hisamitsu Pharmaceutical Co Inc's latest stock split occurred on Jun 27, 2000

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Jun 27, 2000. This was the only stock split in Hisamitsu Pharmaceutical Co Inc's history.

Last Splits:
Jun 27, 2000
2-for-1
Pre-Split Price
N/A
Post-Split Price
2 949.5026
Before
After
Last Splits:
Jun 27, 2000
2-for-1

Hisamitsu Pharmaceutical Co Inc
Stock Splits History

Hisamitsu Pharmaceutical Co Inc Stock Splits Timeline
Jun 27, 2000
Jun 27, 2000
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
2 949.5026
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Mar 28, 2025
Yellow Hat Ltd
OTC:YLLWF
2-for-1
x2
16.93 8.3482 USD 8.465 8.465 USD
Mar 25, 2025
CMC Metals Ltd
XTSX:CMB
1-for-10
/10
0.02 0.2 CAD 0.25 0.25 CAD
Mar 25, 2025
Rent.com.au Ltd
ASX:RNT
63-for-62
x1.0161290322581
0.021 0.0207 AUD 0.018 0.018 AUD
Mar 25, 2025
U
US Critical Metals Corp
OTC:USCMF
1-for-2
/2
0.06 0.15 USD 0.1127 0.1127 USD
Mar 25, 2025
CMC Metals Ltd
F:ZM5P
1-for-10
/10
0.0038 0.038 EUR 0.009 0.009 EUR
Load More

Hisamitsu Pharmaceutical Co Inc
Glance View

Market Cap
301.7B JPY
Industry
Pharmaceuticals

In the bustling landscape of Japanese pharmaceutical companies, Hisamitsu Pharmaceutical Co., Inc. stands out with its pioneering spirit and deep-rooted dedication to health and wellness. Founded in 1847, the company has evolved over a century and a half, transitioning from a modest establishment selling herbal medicines to a globally recognized manufacturer of pain-relief products. At the core of Hisamitsu's operations is its flagship product, the transdermal patch, featuring the SALONPAS brand as its crown jewel. This innovative delivery system allows active medicinal ingredients to penetrate the skin, addressing pain at its source effectively and efficiently. As global demand for non-invasive pain relief grows, Hisamitsu leverages its expertise in transdermal technology, continuously innovating and expanding its product line to cater to diverse consumer needs. Hisamitsu's success hinges on a solid blend of cutting-edge research, consistent quality, and strategic marketing prowess. By investing heavily in R&D, the company not only enhances its existing product offerings but also explores new therapeutic areas, ensuring a pipeline poised for future growth. Besides Japan, Hisamitsu's market presence extends across the Americas, Europe, and Asia, with international sales contributing significantly to its revenue stream. The company is adept at navigating intricate regulatory landscapes and varying consumer preferences to establish its footprint globally. This strategic expansion, coupled with a relentless commitment to quality, enables Hisamitsu to sustain its profitability while fulfilling its mission of delivering comfort and improved quality of life to people around the world.

Intrinsic Value
4 243.72 JPY
Undervaluation 3%
Intrinsic Value
Price
Back to Top